Diagnostic value of protein CD34 in predicting recurrence of TIA or stroke after first TIA

Abstract

TIA is one of the neurological emergencies and can be considered as a serious warning for an impending ischemic stroke. Hence, TIA should be evaluated promptly with imaging and laboratory studies to reduce the risk of subsequent strokes. Despite the conducted studies, the accurate determination of predicting factors of cerebrovascular accidents after TIA still requires more studies. This study aimed to determine the predictive value of CD34 protein in predicting the recurrence of TIA or stroke after primary TIA.

method: In this case-control study, during the year 2023, after obtaining the study ethics code, among the patients who referred to the emergency department with a history of TIA and the same number of patients who referred for a reason other than cerebrovascular diseases as the control group. they started studying. Patients were randomly selected using EXCEL software, and blood samples were taken from these patients, 2 cc of extra blood to check the exact amount of serum CD34 protein using laboratory methods such as PCR or ELISA. It was obtained and analyzed under the conditions to determine the level of this protein; Then, in the 3-month follow-up, it was noted whether the patient was referred or hospitalized due to repeated attacks or stroke.

Results: In the study conducted, 14 patients were examined in the intervention group and 14 in the control group. The average age of the intervention group is 62.79 ± 15.49 and the control group is 29.57 ± 4.48. In the intervention group, 4 patients (28.6%) were men and 10 patients (71.4%) were women, 9 patients were discharged (64.3%) and 5 patients (5.37%) were admitted according to ABCD2 guidelines. . In the three-month follow-up of these patients, we observed that one had a stroke and 13 (92.9%) had no recurrence of symptoms. The average CD34 in the intervention group was 2.46 ± 2.06 mmol/dL, while in the control group this value was 0.62 ± 0.43 mmol/dL. There was a significant difference in the comparison of CD34 levels between the two groups, and its level was much higher in the intervention group. There was no significant relationship between the level of CD34 and the hospital outcome of the patients. There was no significant relationship between the level of CD34 and the rate of recurrence or occurrence of stroke.